Autosomal Dominant Polycystic Kidney Disease Clinical Trial
Official title:
A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)
Recent evidence has shown that kidney volume predicts the likelihood of developing renal
insufficiency over a finite length of time in ADPKD, suggesting a linkage between the growth
of cysts and the harm they do to kidney function. Recent studies indicate that the rate of
kidney volume increase is hastened by excess dietary protein, salt, and potential net acid
precursors, and slowed by increased water intake sufficient to lower plasma vasopressin
levels.
Diets are commonly prescribed to treat ADPKD and other renal patients with disease near the
end-stage, but there is currently no specific diet prescription that takes potentially
harmful dietary elements into account for ADPKD patients in the earliest stages of the
disease. This study will examine a novel diet for ADPKD created by the researcher termed the
ADPKD diet.
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02933268 -
High Water Intake in Polycystic Kidney Disease
|
N/A | |
Completed |
NCT00759369 -
Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
N/A | |
Completed |
NCT00598377 -
Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Completed |
NCT01039987 -
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease
|
N/A | |
Completed |
NCT03717883 -
ADPKD Alterations in Hepatic Transporter Function
|
||
Recruiting |
NCT05193981 -
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
|
||
Completed |
NCT03487913 -
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
|
Phase 2 | |
Not yet recruiting |
NCT06435858 -
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
|
Phase 4 | |
Recruiting |
NCT05190744 -
PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration
|
Phase 2 | |
Recruiting |
NCT05521191 -
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1 | |
Recruiting |
NCT04344769 -
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
||
Active, not recruiting |
NCT02848521 -
A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe
|
||
Completed |
NCT01451827 -
8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 2 | |
Completed |
NCT01210560 -
Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
|
Phase 2 | |
Completed |
NCT01336972 -
Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 2 | |
Completed |
NCT02134899 -
The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
|
Phase 3 | |
Active, not recruiting |
NCT02729662 -
Efficacy of Tolvaptan on ADPKD Patients
|
N/A | |
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Recruiting |
NCT05288998 -
Intrarenal Microvasculature in ADPKD
|
||
Recruiting |
NCT04939935 -
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
|
Phase 3 |